IMPACT OF P2Y12 INHIBITOR CHOICE ON 30-DAY OUTCOMES AFTER PRIMARY PCI: AN ANALYSIS FROM THE EUROMAX TRIAL
2014
We examined the impact of P2Y12 choice on 30-day outcomes, including stent thrombosis (ST), after primary PCI in the EUROMAX trial.
Of 2198 patients, 98% received a loading dose and 89% were placed on maintenance therapy with clopidogrel (CLOP), prasugrel (PRAS) or ticagrelor (TIC) per
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI